OMCL — Omnicell, Inc.

Is OMCL overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Health Information Services

Oversold As of August 19, 2026

Omnicell, Inc. (OMCL) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Health Information Services) last closed at $35.97. The rating moved from Neutral to Oversold on August 18, 2026.

See all oversold Healthcare stocks →

AI analysis

Omnicell, Inc. (OMCL) combines recurring software and services with hardware automation that address rising complexity in medication delivery across hospitals and pharmacies. The company benefits from secular tailwinds—drug complexity, retail pharmacy modernization, and efficiency mandates—that support revenue visibility, though near-term performance depends on hospital capex cycles, competitive bid dynamics, and payer-driven margin pressure. Given current market tone favoring growth and the company’s entrenched position in medication management, catalysts include continued subscription/service growth, new product adoption, and execution on commercial expansion; downside scenarios center on budget-driven delays, competitive pricing pressure, or execution missteps.

Key factors

  • Recurring revenue mix from software, service contracts and consumables provides revenue stability and predictable cash flow
  • Strong market position in pharmacy automation and medication management for hospitals and retail pharmacies, creating high switching costs
  • Addressable market expansion driven by growing drug complexity (biologics, specialty, GLP-1 therapies) and increased demand for automation and adherence solutions
  • Potential upside from secular trends: retail pharmacy modernization, growing focus on medication safety, and hospital/health-system efficiency initiatives
  • Near-term market environment shows mild risk-on flows into growth names which could support multiple expansion
  • Balance sheet and cash flow profile sufficient to fund product development and after-sale service expansion (relative to peers)

Risks

  • Healthcare provider and hospital capital expenditure constraints that could delay hardware deployments and elongate sales cycles
  • Intense competition from established medtech and distribution partners (e.g., BD, McKesson, Swisslog) that can pressure pricing and win rates
  • Payer reimbursement dynamics and insurer/ PBM margin focus that can shift customer priorities and procurement behavior
  • Execution risk on new product rollouts, integration of acquisitions, and maintaining service margins as installed base grows
  • Macroeconomic or inflation-driven budget tightening and upcoming macro data releases that could increase short-term volatility
  • Limited recent SEC/EDGAR signals and neutral social sentiment create potential for information-driven surprises

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for OMCL — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.